Chitungwiza is set to benefit from the rollout of Lenacapavir, a long-acting HIV prevention injection, as part of a phased introduction in 12 high-priority districts across Zimbabwe.
The drug, administered twice yearly, offers protection against HIV and is expected to address challenges with daily pill adherence and stigma associated with frequent clinic visits.
Related Stories
Approximately 46,500 people will receive the injection in the initial phase, prioritizing adolescent girls, young women, sex workers, and other vulnerable groups. The rollout will cover Harare, Bulawayo, Gweru, Masvingo, Mutare, Chitungwiza, Karoi, Mazowe, Tsholotsho, Kwekwe, Shamva, and Gwanda.
Health officials say Lenacapavir will be administered for free to beneficiaries, with the government accessing the drug at a subsidized cost of $40 per year. The Medicines Control Authority of Zimbabwe approved Lenacapavir on November 22, 2025, following a swift 23-day expedited review.
The introduction of Lenacapavir positions Zimbabwe among the first global adopters of this next-generation prevention tool, aiming to curb new infections and accelerate progress toward the UNAIDS 95-95-95 targets.
Leave Comments